InsidersTradesSigma
Track the Retrophin, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 2 February 2016 (Attribution). Among the most active insiders: VALEUR JENSEN MARGARET E. All data is openly available.
Analysts rate Retrophin, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Retrophin, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades raras y trastornos metabólicos. Cotiza en NASDAQ bajo el ticker RTRX.